GlassScriptPhysician profile
Nirav N Shah
NPI 1720299340
$12,722.54
in general payments reported to CMS, 2019-2025
33 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,345 · 2020: $2,193 · 2021: $73.65 · 2022: $331 · 2023: $82.24 · 2024: $291 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,729.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $582.62 | 2019-2025 | Fasenra |
| Glaxosmithkline, LLC. | $377.27 | 2019-2025 | Nucala, Trelegy Ellipta |
| Celgene Corporation | $298.50 | 2019 | |
| Pulmonx Corporation | $284.22 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Boston Scientific Corporation | $153.73 | 2025 | General - Therapies |
| Philips North America LLC | $135.48 | 2019-2020 | |
| Grifols USA, LLC | $112.71 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $96.63 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $88.06 | 2019 | |
| Genzyme Corporation | $81.85 | 2019-2020 | |
| Inspire Medical Systems, INC. | $73.09 | 2023-2024 | Inspire |
| Stryker Corporation | $66.61 | 2020-2022 | |
| Allergan, INC. | $66.09 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $61.21 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.10 | 2019-2020 | |
| Mylan Specialty L.P. | $55.97 | 2019-2022 | |
| Genentech USA, INC. | $54.46 | 2019-2020 | |
| Electronic Waveform Lab, INC. | $48.89 | 2020 | |
| Novartis Pharmaceuticals Corporation | $39.91 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $39.42 | 2019 | |
| Dynasplint Systems INC. | $27.25 | 2025 | Dynasplint |
| Biohaven Pharmaceutical Holding Company LTD. | $24.81 | 2022 | |
| Vapotherm INC | $24.48 | 2019 | |
| Advanced Respiratory, INC | $20.76 | 2019 | |
| Baxter Healthcare | $19.71 | 2022 | |
| Electromed, INC. | $16.35 | 2024 | Smartvest |
| Pfizer INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.15 | 2019 | |
| Amgen INC. | $13.74 | 2024 | Tezspire |
| Shire North American Group INC | $13.64 | 2019 | |
| Insmed, INC. | $13.47 | 2019 | |
| Circassia INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.